• Mon, January 27, 2025

by: Forbes

Super Micro Computer Stock: Where Is It Heading In 2025?

Is Super Micro Computer a good investment in 2025? Get insights into its projected growth, financial outlook, and potential challenges.

by: WOPRAI

Short squeeze is starting in shares of KVUE at $21.49, after crossing above the $21.473 Trigger Price

by: Kiplinger

Stock Market Today: Markets Tumble on DeepSeek Shock

The selloff erased more than $600 billion in market cap from Nvidia stock at one point late in the session, or the biggest one-day rout for a single stock in history. To put the damage in context, Nvidia lost more than the entire market cap of UnitedHealth Group ( UNH ), the nation's largest health insurer and a Buy-rated Dow Jones stock.

by: Investopedia

The Surprising Role Alternative Investments Play in Portfolio Diversification

Alternative investments can help diversify your portfolio and manage risk. These investments include private equity, peer-to-peer lending, commodities, real estate, and crypto. Here's what to consider for each.

by: MoneyWeek

DeepSeek: Chinese chatbot sends shockwaves through US stock market

China's launch of a cheaper, more efficient version of ChatGPT could challenge Silicon Valley's dominance in the AI race

by: WOPRAI

Short squeeze is starting in shares of ESCA at $16.025, after crossing above the $15.896 Trigger Price

by: WOPRAI

Brian Brophy Maintained (ECG) at Buy with Increased Target to $85 on, Jan 24th, 2025

by: WOPRAI

Joshua Chan Maintained (KLC) at Buy with Decreased Target to $28 on, Jan 24th, 2025

by: MSN

Brokers just upgraded these 3 ASX stocks to buys

It's bullish ratings galore for investors this week. The post Brokers just upgraded these 3 ASX stocks to buys appeared first on The Motley Fool Australia.

by: WOPRAI

Stephen Gengaro Maintained (SEI) at Buy with Increased Target to $42 on, Jan 24th, 2025

by: MSN

Karyopharm Therapeutics' SWOT analysis: biotech stock faces pivotal year

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at a critical juncture as it navigates through a challenging biotech landscape while advancing its pipeline of promising drug candidates.

by: MSN

Diworsification: When too much diversification hurts your investments

THERE'S a fine line between diversification and diworsification, and most investors, unknowingly, run right over it. We've all been taught that diversification is the golden rule of investing. Diworsification,

by: WOPRAI

Justin Jenkins Initiated (CCEC) at Outperform and Held Target at $26 on, Jan 24th, 2025

by: WOPRAI

Daniel Ives Maintained (OKLO) at Outperform with Increased Target to $45 on, Jan 24th, 2025

by: MSN

STAG Industrial's SWOT analysis: diverse portfolio shields stock amid market shifts

STAG Industrial, Inc. (NYSE:STAG), a real estate investment trust (REIT) specializing in single-tenant industrial properties across the United States, has been navigating a complex market landscape characterized by shifting demand dynamics and economic uncertainties.

by: MSN

3 Blue-Chip Retail Stocks You Can Trust for Long-Term Gains

Key Takeaways High-risk, high-reward stocks often make headlines, but blue-chip companies are important in any portfolio. Long-term stock gains and consistent growth often follow companies with substantial market capitalization.

by: WOPRAI

Nathan Jones Maintained (VLTO) at Buy with Decreased Target to $116 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (ESAB) at Hold with Increased Target to $131 on, Jan 24th, 2025

by: MSN

The one Australian stock to buy and hold forever in an ASX share portfolio

Buy and hold investing could be your ticket to wealth. Let's see why. The post The one Australian stock to buy and hold forever in an ASX share portfolio appeared first on The Motley Fool Australia.

by: MSN

Billionaires Selling AI Stocks to Buy This ETF that Has 42% Upside According to Wall Street Guru

Investing in the tech sector can be rewarding and risky at the same time. You could have a year like 2021 when tech stocks tumbled, followed by 2023 where they saw highs like never before. But the sector has shown resilience and bounced back from the lows.

by: WOPRAI

Yatin Suneja Reiterated (VIGL) at Buy on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (ZWS) at Hold with Increased Target to $39 on, Jan 24th, 2025

by: WOPRAI

Jeremy Tonet Maintained (DTM) at Neutral with Increased Target to $115 on, Jan 24th, 2025

by: WOPRAI

Grant Joslin Initiated (INDI) at Neutral and Held Target at $4.5 on, Jan 24th, 2025

by: WOPRAI

Andres Coello Maintained (ASTS) at Sector with Decreased Target to $40 on, Jan 24th, 2025

by: WOPRAI

Mark Zhang Initiated (DOCN) at Buy and Held Target at $45 on, Jan 24th, 2025

by: WOPRAI

Li Watsek Reiterated (ALXO) at Overweight on, Jan 24th, 2025

by: WOPRAI

Thiago Batista Upgraded (XP) to Buy and Decreased Target to $16 on, Jan 24th, 2025

by: WOPRAI

Nathan Race Maintained (HBT) at Neutral with Decreased Target to $26 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (HLIO) at Buy with Decreased Target to $60 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (XYL) at Buy with Decreased Target to $150 on, Jan 24th, 2025

by: WOPRAI

Joshua Dennerlein Maintained (WELL) at Buy with Increased Target to $221 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (VMI) at Buy with Increased Target to $387 on, Jan 24th, 2025

by: WOPRAI

Anthony Elian Maintained (VLY) at Overweight and Held Target at $11 on, Jan 24th, 2025

by: WOPRAI

Arvind Ramnani Maintained (V) at Overweight with Increased Target to $368 on, Jan 24th, 2025

by: WOPRAI

Patrick Tyler Brown Reiterated (UNP) at Strong with Increased Target to $285 on, Jan 24th, 2025

by: WOPRAI

Nathan Martin Maintained (UNP) at Buy with Increased Target to $275 on, Jan 24th, 2025

by: WOPRAI

Fadi Chamoun Maintained (UNP) at Outperform with Increased Target to $277 on, Jan 24th, 2025

by: WOPRAI

William Stein Maintained (TXN) at Hold with Decreased Target to $195 on, Jan 24th, 2025

by: WOPRAI

Vijay Rakesh Maintained (TXN) at Neutral with Decreased Target to $190 on, Jan 24th, 2025

by: WOPRAI

William Power Upgraded (TWLO) to Outperform and Increased Target to $160 on, Jan 24th, 2025

by: WOPRAI

Taylor McGinnis Maintained (TWLO) at Buy with Increased Target to $145 on, Jan 24th, 2025

by: WOPRAI

Rishi Jaluria Maintained (TWLO) at Underperform with Increased Target to $75 on, Jan 24th, 2025

by: WOPRAI

Michael Turrin Maintained (TWLO) at Overweight with Increased Target to $155 on, Jan 24th, 2025

by: WOPRAI

Mark Murphy Maintained (TWLO) at Overweight with Increased Target to $130 on, Jan 24th, 2025

by: WOPRAI

Paul Newsome Upgraded (TRV) to Overweight and Increased Target to $310 on, Jan 24th, 2025

by: WOPRAI

Michael Zaremski Maintained (TRV) at Outperform with Increased Target to $297 on, Jan 24th, 2025

by: WOPRAI

Curry Baker Reiterated (TGNA) at Buy and Held Target at $22 on, Jan 24th, 2025

Curry Baker Reiterated (TGNA) at Buy and Held Target at $22 on, Jan 24th, 2025

Curry Baker of Guggenheim, Reiterated "TEGNA Inc." (TGNA) at Buy and Held Target at $22 on, Jan 24th, 2025.

Curry has made no other calls on TGNA in the last 4 months.



There are 3 other peers that have a rating on TGNA. Out of the 3 peers that are also analyzing TGNA, 0 agree with Curry's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Curry

  • Steven Cahall of "Wells Fargo" Upgraded at Overweight and Held Target at $23 on, Thursday, December 19th, 2024
  • David Karnovsky of "JP Morgan" Maintained at Neutral with Increased Target to $19 on, Tuesday, November 12th, 2024
  • Daniel Kurnos of "Benchmark" Maintained at Buy with Increased Target to $23 on, Friday, November 8th, 2024

Like: 👍